General
Preferred name
latamoxef
Synonyms
MOXALACTAM DISODIUM ()
S 6059 ()
FestamoxinLy ()
LY-127935 ()
Shiomarin ()
Latamoxef sodium ()
Antibiotic 6059S ()
6059 S ()
Moxalactam disodium salt ()
Moxalactam (sodium salt) ()
Latamoxef (sodium) ()
Lamoxactam (sodium) ()
LY-127935 (sodium) ()
MOXALACTAM ()
NSC-757107 ()
LY127935 ()
Moxam ()
Latamoxefum dinatricum ()
Latamoxef Disodium ()
Disodium latamoxef ()
Latamoxef ()
P&D ID
PD009373
CAS
64953-12-4
64952-97-2
79120-38-0
Tags
available
drug
Approved by
FDA
Drug indication
bacterial disease
Bacterial infection
Drug Status
approved
investigational
Max Phase
4.0
First approval
1982
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE 29
DESCRIPTION Moxalactam (Latamoxef) sodium salt is a synthetic oxa-¦Â-lactam antibiotic. Moxalactam sodium salt has a broad spectrum of activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria. Moxalactam sodium salt inhibits production of ¦Â-lactamases[1].
TOXICITY Latamoxef produces potentially life-threatening effects which include Bleeding, Hypothrombinemia, Platelet dysfunctioning. which are responsible for the discontinuation of Latamoxef therapy.; The symptomatic adverse reactions produced by Latamoxef are more or less tolerable and if they become severe, they can be treated symptomatically, these include Diarrhea, Skin rashes, Hematuria, Hyperuricemia, Pyuria, Raised serum creatinine.;
DESCRIPTION Latamoxef is an oxacephem molecule developed by the Shionogi Research Laboratories (Osaka, Japan) . It belongs to the β-lactam class of antibacterial compounds. (GtoPdb)
DESCRIPTION Moxalactam sodium salt (LY-127935) is an antibiotic compound more effective against Escherichia coli and Pseudomonas aeruginosathan cephalosporins. (TargetMol Bioactive Compound Library)
Compound Sets
15
ChEMBL Approved Drugs
CHEMBL1200357
CHEMBL74632
ChEMBL Drugs
CHEMBL1200357
CHEMBL74632
DrugBank
DB04570
DrugBank Approved Drugs
DB04570
DrugCentral
1851
DrugCentral Approved Drugs
1851
DrugMAP
DMYKUNR
DMANL0D
DrugMAP Approved Drugs
DMYKUNR
DMANL0D
Guide to Pharmacology
12031
MedChem Express Bioactive Compound Library
HY-B1484
NPC Screening Collection
Other bioactive compounds
ReFrame library
TargetMol Bioactive Compound Library
T6179
The Spectrum Collection
External IDs
52
Properties
(calculated by RDKit )
Molecular Weight
520.1
Hydrogen Bond Acceptors
12
Hydrogen Bond Donors
4
Rotatable Bonds
9
Ring Count
4
Aromatic Ring Count
2
cLogP
-1.13
TPSA
206.3
Fraction CSP3
0.35
Chiral centers
3.0
Largest ring
6.0
QED
0.13
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Antibacterial
antibiotic
Bacterial
Beta-lactamase
Pathway
Microbiology/virology
Anti-infection
Therapeutic Class
Antibiotics
Antiinfective Agents
Source data